English
简体中文
Total: £ 56.28
Published Date: 2025-09-17 | Pages: 77 | Tables: 76 | Medical Care
The global Castrate Resistant Prostate Cancer Therapeutics market size was US$ 18800 million in 2024 and is forecast to a readjusted size of US$ 39170 million by 2031 with a CAGR of 11.2% during the forecast period 2025-2031.
Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels. Many early-stage prostate cancers need normal levels of testosterone to grow, but castrate-resistant prostate cancers do not. Also called CRPC.
The treatment of castration-resistant prostate cancer is to use various methods to treat the recurrence and metastasis of cancer cells or to control hormones.
Global key players of castrate resistant prostate cancer therapeutics include Pfizer, Johnson & Johnson, AstraZeneca, Bayer, Jiangsu Hengrui Pharmaceuticals etc. The top five players hold a share over 70%. North America is the largest market, has a share over 40%, followed by Europe, and Asia-Pacific, with share 28% and 22%, separately.
The global Castrate Resistant Prostate Cancer Therapeutics market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Pfizer/Astellas (Xtandi)
Johnson & Johnson
AstraZeneca/Merck (Lynparza)
Bayer
Jiangsu Hengrui Pharmaceuticals
CTTQ
Sanofi
Hansoh
Clovis Oncology
Zhendong Pharmaceutical
By Type: (Dominant Segment vs High-Margin Innovation)
Hormonal Therapy
Chemotherapy
Others
By Application: (Core Demand Driver vs Emerging Opportunity)
Hospital
Specialty Clinic
Others
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Pfizer/Astellas (Xtandi) in Europe)
- Emerging Product Trends: Hormonal Therapy adoption vs. Chemotherapy premiumization
- Demand-Side Dynamics: Hospital growth in China vs. Specialty Clinic potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
(Additional regions can be customized based on client needs.)
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Castrate Resistant Prostate Cancer Therapeutics market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Chemotherapy in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Specialty Clinic in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Castrate Resistant Prostate Cancer Therapeutics value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Hormonal Therapy
1.2.3 Chemotherapy
1.2.4 Others
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Region (2020-2025)
2.4 Global Castrate Resistant Prostate Cancer Therapeutics Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Castrate Resistant Prostate Cancer Therapeutics Market Size and Prospective (2020-2031)
2.5.2 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size and Prospective (2020-2031)
2.5.3 China Castrate Resistant Prostate Cancer Therapeutics Market Size and Prospective (2020-2031)
2.5.4 Japan Castrate Resistant Prostate Cancer Therapeutics Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Type (2020-2025)
3.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Type (2026-2031)
3.3 Different Types Castrate Resistant Prostate Cancer Therapeutics Representative Players
4 Breakdown Data by Application
4.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Application (2020-2025)
4.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Castrate Resistant Prostate Cancer Therapeutics Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Revenue (2020-2025)
5.1.2 Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Castrate Resistant Prostate Cancer Therapeutics Revenue
5.4 Global Castrate Resistant Prostate Cancer Therapeutics Market Concentration Analysis
5.4.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2024
5.5 Global Key Players of Castrate Resistant Prostate Cancer Therapeutics Head office and Area Served
5.6 Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Product and Application
5.7 Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Castrate Resistant Prostate Cancer Therapeutics Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2020-2025)
6.1.2.2 North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2020-2025)
6.1.3.2 North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Castrate Resistant Prostate Cancer Therapeutics Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2020-2025)
6.2.2.2 Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2020-2025)
6.2.3.2 Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments and Downstream
6.3.1 China Castrate Resistant Prostate Cancer Therapeutics Revenue by Company (2020-2025)
6.3.2 China Market Size by Type
6.3.2.1 China Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2020-2025)
6.3.2.2 China Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2020-2025)
6.3.3 China Market Size by Application
6.3.3.1 China Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2020-2025)
6.3.3.2 China Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2020-2025)
6.3.4 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments and Downstream
6.4.1 Japan Castrate Resistant Prostate Cancer Therapeutics Revenue by Company (2020-2025)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2020-2025)
6.4.2.2 Japan Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2020-2025)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2020-2025)
6.4.3.2 Japan Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2020-2025)
6.4.4 Japan Market Trend and Opportunities
7 Key Players Profiles
7.1 Pfizer/Astellas (Xtandi)
7.1.1 Pfizer/Astellas (Xtandi) Company Details
7.1.2 Pfizer/Astellas (Xtandi) Business Overview
7.1.3 Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Introduction
7.1.4 Pfizer/Astellas (Xtandi) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
7.1.5 Pfizer/Astellas (Xtandi) Recent Development
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Company Details
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Introduction
7.2.4 Johnson & Johnson Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
7.2.5 Johnson & Johnson Recent Development
7.3 AstraZeneca/Merck (Lynparza)
7.3.1 AstraZeneca/Merck (Lynparza) Company Details
7.3.2 AstraZeneca/Merck (Lynparza) Business Overview
7.3.3 AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Introduction
7.3.4 AstraZeneca/Merck (Lynparza) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
7.3.5 AstraZeneca/Merck (Lynparza) Recent Development
7.4 Bayer
7.4.1 Bayer Company Details
7.4.2 Bayer Business Overview
7.4.3 Bayer Castrate Resistant Prostate Cancer Therapeutics Introduction
7.4.4 Bayer Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
7.4.5 Bayer Recent Development
7.5 Jiangsu Hengrui Pharmaceuticals
7.5.1 Jiangsu Hengrui Pharmaceuticals Company Details
7.5.2 Jiangsu Hengrui Pharmaceuticals Business Overview
7.5.3 Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Introduction
7.5.4 Jiangsu Hengrui Pharmaceuticals Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
7.5.5 Jiangsu Hengrui Pharmaceuticals Recent Development
7.6 CTTQ
7.6.1 CTTQ Company Details
7.6.2 CTTQ Business Overview
7.6.3 CTTQ Castrate Resistant Prostate Cancer Therapeutics Introduction
7.6.4 CTTQ Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
7.6.5 CTTQ Recent Development
7.7 Sanofi
7.7.1 Sanofi Company Details
7.7.2 Sanofi Business Overview
7.7.3 Sanofi Castrate Resistant Prostate Cancer Therapeutics Introduction
7.7.4 Sanofi Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
7.7.5 Sanofi Recent Development
7.8 Hansoh
7.8.1 Hansoh Company Details
7.8.2 Hansoh Business Overview
7.8.3 Hansoh Castrate Resistant Prostate Cancer Therapeutics Introduction
7.8.4 Hansoh Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
7.8.5 Hansoh Recent Development
7.9 Clovis Oncology
7.9.1 Clovis Oncology Company Details
7.9.2 Clovis Oncology Business Overview
7.9.3 Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Introduction
7.9.4 Clovis Oncology Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
7.9.5 Clovis Oncology Recent Development
7.10 Zhendong Pharmaceutical
7.10.1 Zhendong Pharmaceutical Company Details
7.10.2 Zhendong Pharmaceutical Business Overview
7.10.3 Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Introduction
7.10.4 Zhendong Pharmaceutical Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
7.10.5 Zhendong Pharmaceutical Recent Development
8 Castrate Resistant Prostate Cancer Therapeutics Market Dynamics
8.1 Castrate Resistant Prostate Cancer Therapeutics Industry Trends
8.2 Castrate Resistant Prostate Cancer Therapeutics Market Drivers
8.3 Castrate Resistant Prostate Cancer Therapeutics Market Challenges
8.4 Castrate Resistant Prostate Cancer Therapeutics Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Castrate Resistant Prostate Cancer Therapeutics Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Share by Region (2020-2025)
Table 6. Global Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Share Forecast by Region (2026-2031)
Table 8. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Type (2020-2025)
Table 10. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Application (2020-2025)
Table 15. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Castrate Resistant Prostate Cancer Therapeutics Application
Table 18. Global Castrate Resistant Prostate Cancer Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Players (2020-2025)
Table 20. Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castrate Resistant Prostate Cancer Therapeutics as of 2024)
Table 21. Ranking of Global Top Castrate Resistant Prostate Cancer Therapeutics Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Castrate Resistant Prostate Cancer Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Headquarters and Area Served
Table 24. Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Product and Application
Table 25. Global Key Players of Castrate Resistant Prostate Cancer Therapeutics, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Castrate Resistant Prostate Cancer Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Company (2020-2025)
Table 29. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Castrate Resistant Prostate Cancer Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Company (2020-2025)
Table 33. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 35. China Castrate Resistant Prostate Cancer Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 36. China Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Company (2020-2025)
Table 37. China Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 38. China Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 39. Japan Castrate Resistant Prostate Cancer Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 40. Japan Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Company (2020-2025)
Table 41. Japan Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 42. Japan Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 43. Pfizer/Astellas (Xtandi) Company Details
Table 44. Pfizer/Astellas (Xtandi) Business Overview
Table 45. Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Product
Table 46. Pfizer/Astellas (Xtandi) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 47. Pfizer/Astellas (Xtandi) Recent Development
Table 48. Johnson & Johnson Company Details
Table 49. Johnson & Johnson Business Overview
Table 50. Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Product
Table 51. Johnson & Johnson Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 52. Johnson & Johnson Recent Development
Table 53. AstraZeneca/Merck (Lynparza) Company Details
Table 54. AstraZeneca/Merck (Lynparza) Business Overview
Table 55. AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Product
Table 56. AstraZeneca/Merck (Lynparza) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 57. AstraZeneca/Merck (Lynparza) Recent Development
Table 58. Bayer Company Details
Table 59. Bayer Business Overview
Table 60. Bayer Castrate Resistant Prostate Cancer Therapeutics Product
Table 61. Bayer Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 62. Bayer Recent Development
Table 63. Jiangsu Hengrui Pharmaceuticals Company Details
Table 64. Jiangsu Hengrui Pharmaceuticals Business Overview
Table 65. Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Product
Table 66. Jiangsu Hengrui Pharmaceuticals Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 67. Jiangsu Hengrui Pharmaceuticals Recent Development
Table 68. CTTQ Company Details
Table 69. CTTQ Business Overview
Table 70. CTTQ Castrate Resistant Prostate Cancer Therapeutics Product
Table 71. CTTQ Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 72. CTTQ Recent Development
Table 73. Sanofi Company Details
Table 74. Sanofi Business Overview
Table 75. Sanofi Castrate Resistant Prostate Cancer Therapeutics Product
Table 76. Sanofi Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 77. Sanofi Recent Development
Table 78. Hansoh Company Details
Table 79. Hansoh Business Overview
Table 80. Hansoh Castrate Resistant Prostate Cancer Therapeutics Product
Table 81. Hansoh Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 82. Hansoh Recent Development
Table 83. Clovis Oncology Company Details
Table 84. Clovis Oncology Business Overview
Table 85. Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Product
Table 86. Clovis Oncology Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 87. Clovis Oncology Recent Development
Table 88. Zhendong Pharmaceutical Company Details
Table 89. Zhendong Pharmaceutical Business Overview
Table 90. Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Product
Table 91. Zhendong Pharmaceutical Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025) & (US$ Million)
Table 92. Zhendong Pharmaceutical Recent Development
Table 93. Castrate Resistant Prostate Cancer Therapeutics Market Trends
Table 94. Castrate Resistant Prostate Cancer Therapeutics Market Drivers
Table 95. Castrate Resistant Prostate Cancer Therapeutics Market Challenges
Table 96. Castrate Resistant Prostate Cancer Therapeutics Market Restraints
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Castrate Resistant Prostate Cancer Therapeutics Product Picture
Figure 2. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Type: 2024 VS 2031
Figure 3. Hormonal Therapy Features
Figure 4. Chemotherapy Features
Figure 5. Others Features
Figure 6. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Application: 2024 VS 2031
Figure 7. Hospital
Figure 8. Specialty Clinic
Figure 9. Others
Figure 10. Castrate Resistant Prostate Cancer Therapeutics Report Years Considered
Figure 11. Global Castrate Resistant Prostate Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 12. Global Castrate Resistant Prostate Cancer Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Region: 2020 VS 2024
Figure 14. North America Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 15. Europe Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. China Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. Japan Castrate Resistant Prostate Cancer Therapeutics Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Players in 2024
Figure 19. Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castrate Resistant Prostate Cancer Therapeutics as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2024
Figure 21. North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2020-2025)
Figure 22. North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2020-2025)
Figure 23. Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2020-2025)
Figure 24. Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2020-2025)
Figure 25. China Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2020-2025)
Figure 26. China Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2020-2025)
Figure 27. Japan Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2020-2025)
Figure 28. Japan Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2020-2025)
Figure 29. Pfizer/Astellas (Xtandi) Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 30. Johnson & Johnson Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 31. AstraZeneca/Merck (Lynparza) Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 32. Bayer Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 33. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 34. CTTQ Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 35. Sanofi Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 36. Hansoh Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 37. Clovis Oncology Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 38. Zhendong Pharmaceutical Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2020-2025)
Figure 39. Bottom-up and Top-down Approaches for This Report
Figure 40. Data Triangulation
Figure 41. Key Executives Interviewed
